我们应该在地球上测量 C 反应蛋白，还是只在 JUPITER 上测量？
Should we measure C-reactive protein on earth or just on JUPITER?
机构信息
Department of Cardiology, Emory University, Atlanta, Georgia, USA.
出版信息
Clin Cardiol. 2010 Apr;33(4):190-8. doi: 10.1002/clc.20681.
Abstract
Evidence for the role of inflammation in the pathogenesis of atherosclerosis is compelling and has generated interest in high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular risk. Data regarding hs-CRP and cardiovascular risk, though largely consistent, is of unclear clinical relevance. Most recently, the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has led to further debate regarding the utility of hs-CRP. This article provides a comprehensive review of the data regarding cardiovascular risk and hs-CRP with an emphasis on the JUPITER trial and concludes with an evidence-based analysis of the current role of hs-CRP in cardiovascular risk assessment.
摘要
有充分的证据表明炎症在动脉粥样硬化的发病机制中起作用，这引起了人们对高敏 C 反应蛋白（hs-CRP）作为心血管风险标志物的兴趣。虽然 hs-CRP 与心血管风险的数据在很大程度上是一致的，但它的临床相关性尚不清楚。最近，他汀类药物在一级预防中的应用的合理性：评价瑞舒伐他汀的干预试验（JUPITER 试验）进一步引发了关于 hs-CRP 效用的争论。本文对心血管风险和 hs-CRP 的相关数据进行了全面的回顾，重点介绍了 JUPITER 试验，并对 hs-CRP 在心血管风险评估中的当前作用进行了基于证据的分析。
相似文献
1
Should we measure C-reactive protein on earth or just on JUPITER?
Clin Cardiol. 2010 Apr;33(4):190-8. doi: 10.1002/clc.20681.
2
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1.
3
Jupiter to Earth: CRP promotes atherothrombosis.
Metab Syndr Relat Disord. 2009 Feb;7(1):1-3. doi: 10.1089/met.2009.EDI.
4
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812.
5
Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
Int J Occup Environ Health. 2012 Jan-Mar;18(1):70-8. doi: 10.1179/1077352512Z.0000000008.
6
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
Vasc Health Risk Manag. 2009;5:1033-42. doi: 10.2147/vhrm.s6412. Epub 2009 Dec 29.
7
The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial.
Curr Atheroscler Rep. 2011 Apr;13(2):154-61. doi: 10.1007/s11883-011-0164-5.
8
Expanding the orbit of primary prevention--moving beyond JUPITER.
N Engl J Med. 2008 Nov 20;359(21):2280-2. doi: 10.1056/NEJMe0808320. Epub 2008 Nov 9.
9
Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
JAMA Intern Med. 2015 Feb;175(2):171-7. doi: 10.1001/jamainternmed.2014.6388.
10
Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr. 2008 Nov-Dec;19(6):332-4, discussion 335.
引用本文的文献
1
Modification of associations between indoor particulate matter and systemic inflammation in individuals with COPD.
Environ Res. 2022 Jun;209:112802. doi: 10.1016/j.envres.2022.112802. Epub 2022 Jan 29.
2
Statins in Healthy Adults: A Meta-Analysis.
Medicina (Kaunas). 2021 Jun 7;57(6):585. doi: 10.3390/medicina57060585.
3
Indoor black carbon and biomarkers of systemic inflammation and endothelial activation in COPD patients.
Environ Res. 2018 Aug;165:358-364. doi: 10.1016/j.envres.2018.05.010. Epub 2018 May 18.
4
Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease.
Am J Pathol. 2017 Dec;187(12):2895-2911. doi: 10.1016/j.ajpath.2017.08.006. Epub 2017 Nov 16.
5
Effects of a Low Dose of Fish Oil on Inflammatory Markers of Brazilian HIV-Infected Adults on Antiretroviral Therapy: A Randomized, Parallel, Placebo-Controlled Trial.
Nutrients. 2015 Aug 5;7(8):6520-8. doi: 10.3390/nu7085294.
6
Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.
Arch Pathol Lab Med. 2014 Feb;138(2):189-203. doi: 10.5858/arpa.2013-0149-OA. Epub 2013 Jun 5.
7
Elevated C-reactive protein is associated with severe periodic leg movements of sleep in patients with restless legs syndrome.
Brain Behav Immun. 2012 Nov;26(8):1239-43. doi: 10.1016/j.bbi.2012.06.003. Epub 2012 Jun 26.
8
C-reactive protein, early life stress, and wellbeing in healthy adults.
Acta Psychiatr Scand. 2012 Dec;126(6):402-10. doi: 10.1111/j.1600-0447.2012.01892.x. Epub 2012 Jun 11.
9
High-sensitivity C-reactive protein and mobility disability in older adults.
Age Ageing. 2012 Jul;41(4):541-5. doi: 10.1093/ageing/afs038. Epub 2012 Mar 14.
10
Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.
J Lipid Res. 2012 Jan;53(1):51-65. doi: 10.1194/jlr.M019927. Epub 2011 Oct 23.
本文引用的文献
1
From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):41-8. doi: 10.1161/CIRCOUTCOMES.108.832592. Epub 2009 Jan 13.
2
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.
Circulation. 2009 May 5;119(17):2408-16. doi: 10.1161/CIRCULATIONAHA.109.192278. Epub 2009 Apr 13.
3
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.
4
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.
5
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
6
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.
Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251. doi: 10.1161/CIRCULATIONAHA.108.814251. Epub 2008 Nov 9.
7
Genetically elevated C-reactive protein and ischemic vascular disease.
N Engl J Med. 2008 Oct 30;359(18):1897-908. doi: 10.1056/NEJMoa0707402.
8
C-reactive protein and coronary heart disease: a critical review.
J Intern Med. 2008 Oct;264(4):295-314. doi: 10.1111/j.1365-2796.2008.02015.x.
9
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
JAMA. 2007 Feb 14;297(6):611-9. doi: 10.1001/jama.297.6.611.
10
Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2745-51. doi: 10.1161/01.ATV.0000248096.62495.73. Epub 2006 Sep 28.
Zotero 插件